A multiplication problem.

TL;DR: Revascularization in patients with NARAD, such as ECD, should be managed in an open approach because of the superior long-term graft patency and blood pressure control in a disease where progression to vessel fibrosis and atherosclerosis could interfere with endovascular stent patency.

TL;DR: Erdheim-Chester disease is a rare, non-Langerhans form of histiocytosis of unknown origin characterized by xanthomatous or xanthogranulomatously infiltration of tissues by spumous ("foamy") histiocytes, characterized by heterogeneous systemic manifestations.

TL;DR: Treating 3 patients with advanced disease with interferon-α at a starting dose of 3 to 6 × 106 units, which was later reduced, during maintenance, to 1 ×106 units subcutaneous 3 times per week suggests that this well-tolerated therapy has a significant effect on the course and outcome of Erdheim-Chester disease.

TL;DR: Patients with Erdheim-Chester disease show markedly disparate clinical courses and some features similar to Hand-Schüller-Christian disease and need careful monitoring and further attempts at treatment.

TL;DR: This work describes 3 unusual cases of Erdheim-Chester disease with periaortic fibrosis involving the whole aorta and leading to a "coated aortsa" appearance on computed tomography scans.